Loading organizations...

§ Private Profile · Boston, MA, USA
Healthtech startup developing standalone kiosks for AI-powered 90-second vision tests, delivering prescriptions in retail.
Boston-based Eyebot develops standalone kiosks that utilize artificial intelligence and precision optics to deliver clinically validated, 90-second vision tests for eyeglass prescriptions without requiring an on-site optometrist. The healthtech company deploys these automated terminals across various retail environments, grocery stores, and shopping centers, having already conducted over 50,000 vision tests for everyday consumers. Operating with a staff of 28 employees, the firm provides remote doctor reviews to issue medical prescriptions within 24 hours and is currently scaling its operations to handle over 500,000 annual tests by 2026. To date, Eyebot has raised approximately $30 million in total funding, which includes a recent $20 million Series A financing round backed by prominent venture capital firms such as General Catalyst, AlleyCorp, Baukunst, and Village Global. The enterprise was founded in 2021 by Matthias Hofmann and Jack Moldave.
Eyebot has raised $28.0M across 3 funding rounds.
Eyebot has raised $28.0M in total across 3 funding rounds.
Eyebot has raised $28.0M across 3 funding rounds. Most recently, it raised $20.0M Series A in August 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2025 | $20M Series A | Caitlin Donovan | AlleyCorp, Baukunst, Grit Ventures, Humba Ventures, Ravelin Capital, SOSV, Ubiquity Ventures, Village Global, Ravelin | Announced |
| Jun 1, 2024 | $6M Seed | AlleyCorp, Ubiquity Ventures | Baukunst, Grit Ventures, Humba Ventures, Ravelin Capital, SOSV, Village Global, Ravelin, Spacecadet Ventures | Announced |
| Sep 1, 2022 | $2M Seed | — | AlleyCorp, Baukunst, Humba Ventures, Ravelin Capital, Ubiquity Ventures, Village Global | Announced |
Eyebot has raised $28.0M in total across 3 funding rounds.
Eyebot's investors include Caitlin Donovan, AlleyCorp, Baukunst, Grit Ventures, Humba Ventures, Ravelin Capital, SOSV, Ubiquity Ventures, Village Global, Ravelin, Spacecadet Ventures.
Eyebot is a technology company developing automated kiosks that deliver 90-second, self-serve vision tests, generating eyeglass prescriptions reviewed by licensed eye doctors, without appointments or insurance.[1][2][3] It serves retail environments like malls, universities, grocery stores, and optical shops, solving accessibility barriers in vision care—such as long waits, high costs, and limited provider availability—while enabling retailers to expand services efficiently.[1][2][4] Since its 2021 founding, Eyebot has raised $6M in seed funding and $20M in Series A, completed over 45,000 tests, and plans national scaling with pilots showing strong reception.[1][2]
Eyebot was founded in March 2021 by Matthias Hofmann, Ph.D., who serves as CEO and brings a decade of experience, including a patented refraction engine central to the kiosks.[1][4] Hofmann's background in deep tech drove the idea of "push-button vision testing" to address widespread undiagnosed vision issues and barriers in corrective eyewear access.[1][5] Early traction came from soft launches with positive feedback, leading to seed funding in 2024 from AlleyCorp, Ubiquity Ventures, and others, followed by a $20M Series A led by General Catalyst.[1][2] Pivotal moments include IRB-approved clinical validation with over 2,600 patients and deployment in real-world settings.[4][6]
Eyebot rides the wave of AI-driven health assurance, applying supervised AI to condense specialist eye exams into self-serve kiosks, meeting consumers where they shop amid rising demand for proactive, affordable care.[2][4] Timing aligns with strong investor interest in AI-health hybrids and post-pandemic shifts toward accessible retail health tech, addressing U.S. vision care gaps where millions lack glasses or screenings.[1][5] Favorable market forces include retail efficiency needs and regulatory support for telehealth; Eyebot influences the ecosystem by partnering with retailers and doctors, boosting early disease detection and enabling new storefront models.[2][4]
Eyebot is poised for explosive growth, targeting 5,000+ U.S. locations to reach 97% of the population within 10 minutes, with international expansion and R&D for disease screening.[1][2] Trends like AI hardware integration and retail health embeds will propel it, evolving its role from kiosks to a vision care platform influencing global access. This builds on its mission—delivering prescriptions at the touch of a button—positioning Eyebot as a leader in equitable, tech-powered eye health.[3][4]